Wall Street analysts expect Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to announce $573.85 million in sales for the current fiscal quarter, according to Zacks. Seven analysts have issued estimates for Jazz Pharmaceuticals' earnings, with the highest sales estimate coming in at $582.28 million and the lowest estimate coming in at $562.70 million. Jazz Pharmaceuticals posted sales of $537.70 million during the same quarter last year, which suggests a positive year-over-year growth rate of 6.7%. The business is expected to issue its next earnings results on Tuesday, November 3rd.
On average, analysts expect that Jazz Pharmaceuticals will report full year sales of $2.27 billion for the current year, with estimates ranging from $2.25 billion to $2.32 billion. For the next fiscal year, analysts anticipate that the firm will report sales of $2.49 billion, with estimates ranging from $2.36 billion to $2.66 billion. Zacks' sales calculations are an average based on a survey of sell-side research analysts that cover Jazz Pharmaceuticals.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, August 4th. The specialty pharmaceutical company reported $3.71 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $3.11 by $0.60. The business had revenue of $562.44 million during the quarter, compared to analysts' expectations of $503.19 million. Jazz Pharmaceuticals had a return on equity of 20.47% and a net margin of 6.01%. The business's quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.05 EPS.
A number of equities analysts have recently issued reports on the company. Morgan Stanley raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and set a $177.00 target price for the company in a research note on Thursday, August 6th. They noted that the move was a valuation call. Oppenheimer began coverage on Jazz Pharmaceuticals in a research note on Thursday, July 30th. They issued an "outperform" rating for the company. Royal Bank of Canada raised their price objective on Jazz Pharmaceuticals from $160.00 to $170.00 in a research note on Monday, September 14th. SVB Leerink raised their price objective on Jazz Pharmaceuticals from $164.00 to $182.00 and gave the company an "outperform" rating in a research note on Friday, October 9th. Finally, Goldman Sachs Group downgraded Jazz Pharmaceuticals from a "neutral" rating to a "sell" rating and set a $128.00 price objective for the company. in a research note on Monday, September 14th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and seventeen have assigned a buy rating to the company's stock. The company presently has a consensus rating of "Buy" and a consensus price target of $166.25.
In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 4,500 shares of the firm's stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $141.94, for a total value of $638,730.00. Following the transaction, the chief executive officer now directly owns 332,180 shares of the company's stock, valued at $47,149,629.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bruce C. Cozadd sold 3,000 shares of the firm's stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $130.00, for a total value of $390,000.00. The disclosure for this sale can be found here. Insiders sold 8,363 shares of company stock worth $1,142,374 in the last quarter. 4.60% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. LSV Asset Management boosted its position in shares of Jazz Pharmaceuticals by 19.5% during the second quarter. LSV Asset Management now owns 2,225,431 shares of the specialty pharmaceutical company's stock worth $245,554,000 after buying an additional 363,015 shares during the period. Thompson Siegel & Walmsley LLC bought a new stake in Jazz Pharmaceuticals during the second quarter worth approximately $36,250,000. Point72 Asset Management L.P. raised its holdings in Jazz Pharmaceuticals by 1,424.8% during the second quarter. Point72 Asset Management L.P. now owns 346,139 shares of the specialty pharmaceutical company's stock worth $38,193,000 after purchasing an additional 323,439 shares in the last quarter. Sarissa Capital Management LP raised its holdings in Jazz Pharmaceuticals by 72.5% during the first quarter. Sarissa Capital Management LP now owns 765,000 shares of the specialty pharmaceutical company's stock worth $76,301,000 after purchasing an additional 321,500 shares in the last quarter. Finally, Sofinnova Investments Inc. bought a new stake in Jazz Pharmaceuticals during the second quarter worth approximately $26,851,000. 92.82% of the stock is currently owned by institutional investors and hedge funds.
JAZZ opened at $147.72 on Tuesday. The business has a 50 day moving average price of $142.04 and a two-hundred day moving average price of $120.03. The company has a quick ratio of 5.39, a current ratio of 5.62 and a debt-to-equity ratio of 0.66. The company has a market cap of $8.19 billion, a PE ratio of 63.95, a P/E/G ratio of 4.42 and a beta of 1.15. Jazz Pharmaceuticals has a 52 week low of $86.88 and a 52 week high of $156.26.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
See Also: What is the return on assets (ROA) ratio?
Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Portfolio
Almost everyone loves a company that pays strong dividends. Who doesn't like receiving a check every quarter for simply owning a stock--especially if that stock is paying you back 4%, 5% or even 10% of its share price in annual income each year?. In a world where 10-year treasuries are yielding just above 2%, it seems hard to go wrong when buying a stock that's yielding significantly above the going rates on fixed-income assets. Unfortunately, the market rarely offers a free lunch.
While high-yield stocks may have a lot of near-term attractiveness, those same high-yields can often signal significant danger ahead. In some cases, it might mean that the company's dividend will stop growing or won't grow as fast as it used to. Worse yet, the company could cut its dividend, reduce the income you receive from owning the stock and drive down the value of the shares that you own.
4%-plus yields might seem like an easy opportunity to boost the investment income you receive, but high-yield stocks can just as often be a track reading to snare unsuspecting investors. It's not always easy to tell the difference though.
This slideshow highlights 10 high-yield dividend stocks that are paying an unsustainably large percentage of their earnings in the form of a dividend. These companies are all paying out more than 100% of their earnings per share in the form of a dividend, a sign that the advertised high-yield probably won't last.
View the "20 High-Yield Dividend Stocks that Could Ruin Your Retirement Portfolio".